Share chart Gilead Sciences
Extended chart
Simple chart
About Gilead Sciences
Gilead Sciences, Inc., биофармацевтическая компания, основанная на исследованиях, обнаруживает, разрабатывает и продает лекарства для удовлетворения неудовлетворенных медицинских потребностей в США, Европе и на международном уровне. Компания предоставляет продукты Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera / Eviplera, Stribild и Atripla для лечения инфекции, вызванной вирусом иммунодефицита человека (ВИЧ); Веклуры, инъекция для внутривенного введения, для лечения коронавирусной болезни 2019; и Epclusa, Harvoni, Vosevi, Vemlidy и Viread для лечения заболеваний печени. more detailsMain settings
IPO date
1992-01-22
ISIN
US3755581036
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
2.78
Дивиденд ао
0.79
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 4.02 | 4 |
| P/BV | 6 | 2 |
| P/E | 240.57 | 1 |
Efficiency
| Title | Value | Grade |
| ROA | 0.7926 | 1 |
| ROE | 2.28 | 1 |
| ROIC | 11.06 | 4 |
Dividends
| Title | Value | Grade |
| Dividend yield | 3.16 | 7.9 |
| DSI | 0.9286 | 9.29 |
| Average dividend growth | 4.04 | 6.74 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | 6.02 | 0 |
| Debt/Ratio | 0.4528 | 10 |
| Debt/Equity | 2.07 | 6 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 16.46 | 3 |
| Yield Ebitda, % | -47.9 | 0 |
| Yield EPS, % | 442.51 | 10 |
Dividends
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 108 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 109.3 $ | 108 $ | 108 $ | -1.19 % | 0 % | 0 % |
| Month | 107.37 $ | 107.37 $ | 113 $ | 0.59 % | 0 % | 0 % |
| Three month | 103.63 $ | 96.91 $ | 113 $ | 4.22 % | 0 % | 0 % |
| Half a year | 96.04 $ | 89.14 $ | 117.41 $ | 12.45 % | 0 % | 0 % |
| Year | 79 $ | 66.59 $ | 117.41 $ | 36.71 % | 0 % | 0 % |
| 3 years | 65.1 $ | 59.54 $ | 117.41 $ | 65.9 % | 0 % | 0 % |
| 5 years | 63.99 $ | 56.65 $ | 117.41 $ | 68.78 % | 0 % | 0 % |
| 10 years | 74.1 $ | 56.65 $ | 118.87 $ | 45.75 % | 0 % | 0 % |
| Year to date | 103.31 $ | 89.14 $ | 117.41 $ | 4.54 % | 0 % | 0 % |
Insider trading
Main owners
Contained in ETF
ETF | Share, % | Profitability for 1 year, % | Commission, % |
| Future Tech ETF | 8.5029 | -18.13 | 0.35 |
| Principal Healthcare Innovators ETF | 8.5029 | -3.92 | 0.35 |
| iShares Evolved U.S. Innovative Healthcare ETF | 4.1 | 0.000586 | 0.18 |
| Pacer BioThreat Strategy ETF | 3.56666 | 6.83 | 0.7 |
| 2nd Vote Life Neutral Plus ETF | 3.36 | 0 | 0.75 |
| Donoghue Forlines Innovation ETF | 1.90015 | 18.15 | 0.69 |
| John Hancock Multifactor Healthcare ETF | 1.62 | 29.34 | 0.40 |
| FCF US Quality ETF | 1.49429 | 9.78 | 0.59 |
| Nationwide Maximum Diversification U.S. Core Equity ETF | 1.3 | 26.65 | 0.34 |
| VanEck Morningstar Global Wide Moat ETF | 1.0755 | 11.32 | 0.52 |
| Nationwide Nasdaq-100 Risk-Managed Income ETF | 0.71563 | 3.32 | 0.68 |
| JPMorgan Corporate Bond Research Enhanced ETF | 0.41 | 1.94 | 0.09 |
| iShares Morningstar Large-Cap Value ETF | 0.40345 | 53.47 | 0.25 |
| Columbia U.S. ESG Equity Income ETF | 0.3637 | -3.6 | 0.35 |
| iShares Morningstar Large-Cap ETF | 0.20825 | 184.21 | 0.03 |
| 2.5 | 21.29 | 0.42 |
|---|
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Andrew D. Dickinson | Chief Financial Officer | 2.66M | 1970 (55 years) |
| Ms. Johanna Mercier | Chief Commercial Officer | 3.1M | 1970 (55 years) |
| Dr. Merdad V. Parsey M.D., Ph.D. | Chief Medical Officer | 2.79M | 1963 (62 years) |
| Ms. Jacquie Ross C.F.A. | Vice President of Investor Relations | N/A | |
| Ms. Jyoti K. Mehra | Executive Vice President of Human Resources | N/A | 1977 (48 years) |
| Dr. Linda Slanec Higgins Ph.D. | Senior Vice President of Research, Innovation & Portfolio | N/A | 1962 (63 years) |
| Ms. Sandra Patterson | Senior VP, Corporate Controller & Principal Accounting Officer | N/A | 1967 (58 years) |
| Dr. Rudolf Ertl | Senior Vice President of Commercial Operations of Australia, Canada, Europe | N/A | 1946 (79 years) |
| Mr. Daniel P. O'Day | Chairman & CEO | 1964 (61 year) | |
| Ms. Deborah H. Telman | Executive VP of Corporate Affairs, General Counsel & Corporate Secretary | 1965 (60 years) |
About company
Address: United States, Foster City, 333 Lakeside Drive - Open in google maps, Open in yandex maps
Website: http://www.gilead.com
Website: http://www.gilead.com
